SEC Form 4 · accession 0001140361-16-087000
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew H Galligan
Officer — Chief Financial Officer
Period of report
Nov 15, 2016
Accepted (ET)
Nov 16, 2016 · 6:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 15, 2016 | M | 3,315 | $3.60 | A | 33,315 | D | |
| Common Stock | Nov 15, 2016 | M | 4,185 | $18.00 | A | 37,500 | D | |
| Common StockF2 | Nov 15, 2016 | S | 200 | $84.165 | D | 37,300 | D | |
| Common StockF3 | Nov 15, 2016 | S | 660 | $85.7013 | D | 36,640 | D | |
| Common StockF4 | Nov 15, 2016 | S | 3,734 | $86.7546 | D | 32,906 | D | |
| Common StockF5 | Nov 15, 2016 | S | 2,906 | $87.5486 | D | 30,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $3.60 | Nov 15, 2016 | M | 3,315 | D | — | Sep 28, 2021 | Common Stock | 3,315 | 59,546 | D |
| Stock Option (right to buy)F7 | $18.00 | Nov 15, 2016 | M | 4,185 | D | — | Nov 4, 2024 | Common Stock | 4,185 | 42,667 | D |
Explanation of responses
- F1The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.14 to $84.19, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.17 to $86.08, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $86.24 to $87.13, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $87.27 to $87.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6100% of the shares subject to the option are fully vested and exercisable.
- F71/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2014 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.